Protagonist Therapeutics (PTGX) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Protagonist Therapeutics, as the data feed reports them.

Analysts' mean target, 14 analysts
$182.36
46.3% above the price

The 14 analysts reported by the data feed have a mean price target for Protagonist Therapeutics of $182.36, 46.3% above the $124.67 price (range $151.00–$225.00). 18.23% of the float was sold short as of Oct 30, 2026. Institutions hold 115.1% of the shares and insiders 0.7%. Source: Yahoo Finance, read Nov 18, 2026.

Key facts

Analysts' mean target
$182.36+46.3% vs price
Analysts
14
Short interest
18.23%of float, Oct 30, 2026
Short ratio
13.75 days
Institutions
115.1%
Insiders
0.70%
Beta
1.22

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

14 analysts covering Protagonist Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $124.67.

Analysts' price targets for Protagonist Therapeutics
Mean price target$182.3646.3% above the price (+46.3%)
Median price target$181.0045.2% above the price (+45.2%)
Highest target$225.0080.5% above the price (+80.5%)
Lowest target$151.0021.1% above the price (+21.1%)
Analysts with a target14

Ratings this month · 14 analysts

Strong buy 3(21%)Buy 11(79%)
Analysts' ratings of Protagonist Therapeutics this month, by rating
RatingAnalystsShare
Strong buy321%
Buy1179%
Hold00%
Sell00%
Strong sell00%

The feed averages these to 1.21 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns Protagonist Therapeutics

Ownership of Protagonist Therapeutics
Held by institutions115.1%527 institutions; percent of shares outstanding
Held by institutions, of the float115.9%
Held by insiders0.70%percent of shares outstanding
Shares outstanding65.27M
Float53.45Mshares available to trade
Insiders' net purchases, six months+5106 purchases (252.51K shares), 5 sales (252K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Protagonist Therapeutics
Shares short10.24Mas of Oct 30, 2026
Percent of float18.23%shares short ÷ float
Percent of shares outstanding15.71%shares short ÷ shares outstanding
Short ratio (days to cover)13.75shares short ÷ average daily volume

Protagonist Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Protagonist Therapeutics
Beta1.22movement against the market; 1 moves with it
52-week high$160.81
52-week low$77.00
Average volume, 3 months668.58Kshares a day
Average volume, 10 days634.21Kshares a day

Questions and answers

What is the analysts' price target for Protagonist Therapeutics (PTGX)?

As reported by the data feed, the mean price target of the 14 analysts covering Protagonist Therapeutics is $182.36, 46.3% above the latest price of $124.67. The highest target is $225.00 and the lowest $151.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Protagonist Therapeutics stock?

Of the 14 ratings the data feed reports for the current month, 3 are strong buy, 11 buy, 0 hold, 0 sell and 0 strong sell.

How many Protagonist Therapeutics shares are sold short?

As reported by the data feed, 10.24M shares were sold short, 18.23% of the float as of Oct 30, 2026. At the average daily volume that is 13.75 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Protagonist Therapeutics stock?

As reported by the data feed, institutions hold 115.1% of the shares (527 institutions) and insiders 0.7%. There are 65.27M shares outstanding, of which 53.45M are in the float.

How much does Protagonist Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 1.22: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $77.00 and $160.81.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) statistics and analyst targets”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/statistics

Underlying data: Yahoo Finance.